Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:BEAM NASDAQ:RAPP NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.21+0.1%$35.93$23.42▼$62.58$2.10B0.81.09 million shs1.17 million shsBEAMBeam Therapeutics$18.70-2.2%$18.74$13.52▼$35.25$1.92B2.222.45 million shs3.75 million shsRAPPRapport Therapeutics$14.43+2.8%$12.85$6.43▼$29.74$512.43M0.62159,669 shs206,792 shsXENEXenon Pharmaceuticals$34.40+3.7%$31.58$26.74▼$46.00$2.54B1.16877,655 shs2.36 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.14%-4.03%+0.43%+28.54%-14.98%BEAMBeam Therapeutics-2.20%-6.17%-6.59%+15.22%-26.98%RAPPRapport Therapeutics+2.78%-6.42%+19.85%+41.19%-29.68%XENEXenon Pharmaceuticals+3.74%+11.44%-0.88%-2.63%-17.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.0551 of 5 stars3.41.00.04.32.40.81.9BEAMBeam Therapeutics2.7916 of 5 stars3.51.00.00.03.82.50.6RAPPRapport Therapeutics1.2126 of 5 stars3.50.00.00.00.60.80.6XENEXenon Pharmaceuticals3.109 of 5 stars4.51.00.00.03.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.75Moderate Buy$56.3355.57% UpsideBEAMBeam Therapeutics 3.07Buy$48.75160.70% UpsideRAPPRapport Therapeutics 3.00Buy$28.0094.04% UpsideXENEXenon Pharmaceuticals 3.00Buy$54.8259.36% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, XENE, AGIO, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$71.00 ➝ $65.007/22/2025AGIOAgios PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$52.00 ➝ $51.007/21/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.005/14/2025XENEXenon PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.005/13/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.005/13/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$53.00 ➝ $53.005/13/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.00(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M57.64N/AN/A$23.57 per share1.54BEAMBeam Therapeutics$63.52M29.60N/AN/A$8.86 per share2.11RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/AXENEXenon Pharmaceuticals$9.43M279.91N/AN/A$9.90 per share3.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.003.29N/AN/A1,590.42%-3.49%-3.23%N/ABEAMBeam Therapeutics-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%N/ARAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/11/2025 (Estimated)Latest RAPP, XENE, AGIO, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RAPPRapport Therapeutics-$0.87N/AN/AN/AN/AN/A8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03N/AN/AN/AN/AN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 million5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/A5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.4814.04BEAMBeam TherapeuticsN/A8.818.81RAPPRapport TherapeuticsN/A31.0131.01XENEXenon PharmaceuticalsN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ABEAMBeam Therapeutics99.68%RAPPRapport TherapeuticsN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%BEAMBeam Therapeutics3.50%RAPPRapport TherapeuticsN/AXENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39058.10 million55.24 millionOptionableBEAMBeam Therapeutics510100.56 million97.04 millionOptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/AXENEXenon Pharmaceuticals21076.73 million72.50 millionOptionableRAPP, XENE, AGIO, and BEAM HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Issues Equity Inducement Grants to New Employees1 hour ago | theglobeandmail.comXenon Pharmaceuticals (NASDAQ:XENE) Trading 7.1% Higher - Still a Buy?August 5 at 2:08 PM | marketbeat.comXenon to Report Q2 2025 Financial Results on August 11, 2025August 4 at 8:38 AM | financialpost.comFXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by BIT Capital GmbHAugust 4 at 8:32 AM | marketbeat.comXenon to Report Q2 2025 Financial Results on August 11, 2025August 4 at 8:01 AM | globenewswire.comJ. Safra Sarasin Holding AG Has $1.03 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)August 4 at 3:50 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by AnalystsAugust 4 at 3:00 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Federated Hermes Inc.August 3 at 3:28 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Sees Large Growth in Short InterestAugust 3 at 2:21 AM | americanbankingnews.comShort Interest in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expands By 6,945.5%August 2, 2025 | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.com11,949 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Y Intercept Hong Kong LtdJuly 29, 2025 | marketbeat.comLegato Capital Management LLC Takes $323,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 26, 2025 | marketbeat.comInvestors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)July 24, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Bank of New York Mellon CorpJuly 23, 2025 | marketbeat.comNew York State Common Retirement Fund Buys 9,851 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 22, 2025 | marketbeat.comMutual of America Capital Management LLC Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 21, 2025 | marketbeat.comJennison Associates LLC Sells 24,860 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 20, 2025 | marketbeat.comCenterBook Partners LP Makes New $745,000 Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 18, 2025 | marketbeat.comTimesSquare Capital Management LLC Has $25.01 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)July 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?This Drone Stock Is on Sale Despite Big Army ContractBy Jeffrey Neal Johnson | July 31, 2025View This Drone Stock Is on Sale Despite Big Army ContractSpotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?By Leo Miller | July 31, 2025View Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RAPP, XENE, AGIO, and BEAM Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$36.21 +0.05 (+0.14%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$34.84 -1.38 (-3.80%) As of 08/5/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Beam Therapeutics NASDAQ:BEAM$18.70 -0.42 (-2.20%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$18.49 -0.21 (-1.12%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Rapport Therapeutics NASDAQ:RAPP$14.43 +0.39 (+2.78%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$14.63 +0.20 (+1.39%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Xenon Pharmaceuticals NASDAQ:XENE$34.40 +1.24 (+3.74%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$38.55 +4.15 (+12.06%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Soars After Blowout Earnings Report Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? Applied Digital: Why a Surge in Bullish Bets Signals a New Era META Gets Huge Upgrades: How High Analysts Think Shares Could Go Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
